Mark M. Awad, MD, PhD

Mark Awad, MD, PhD, discusses the significance of the FDA approval of perioperative nivolumab for patients with resectable NSCLC.

Mark M. Awad, MD, PhD, discusses the main objectives of the phase 2 GEOMETRY mono-1 study in patients with MET exon 14 skipping (METex14)-mutated non–small cell lung cancer (NSCLC).

Mark M. Awad, MD, PhD, discusses acquired resistance to MET inhibitors in MET exon 14 skipping (METex14)–mutated non–small cell lung cancer (NSCLC).